Zynex (NASDAQ:ZYXI) Updates Q4 2024 Earnings Guidance

Zynex (NASDAQ:ZYXI) issued an update on its fourth quarter 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.090- for the period, compared to the consensus estimate of 0.100. The company issued revenue guidance of $53.6 million-, compared to the consensus revenue estimate of $53.3 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.

Zynex Price Performance

Shares of ZYXI traded up $0.23 during trading hours on Thursday, hitting $8.59. 151,606 shares of the company were exchanged, compared to its average volume of 173,447. The company has a market capitalization of $272.65 million, a PE ratio of 47.72 and a beta of 0.54. The company has a debt-to-equity ratio of 1.79, a current ratio of 4.06 and a quick ratio of 3.22. The firm has a fifty day simple moving average of $7.96 and a 200-day simple moving average of $9.23. Zynex has a one year low of $7.04 and a one year high of $13.77.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $49.88 million for the quarter, compared to the consensus estimate of $51.99 million. Zynex had a return on equity of 14.15% and a net margin of 3.12%. The business’s revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.09 earnings per share. As a group, sell-side analysts predict that Zynex will post 0.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Zynex in a report on Wednesday, September 4th. Royal Bank of Canada reduced their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Insider Buying and Selling

In other news, Director Joshua R. Disbrow acquired 7,000 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average cost of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the acquisition, the director now owns 72,000 shares in the company, valued at approximately $599,040. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Joshua R. Disbrow acquired 7,000 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average cost of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the acquisition, the director now owns 72,000 shares in the company, valued at approximately $599,040. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Anna Lucsok sold 8,083 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total value of $64,906.49. Following the sale, the chief operating officer now owns 16,980 shares of the company’s stock, valued at approximately $136,349.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 52.13% of the stock is owned by corporate insiders.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.